CorMedix (CRMD) vs Indaptus Therapeutics (INDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Indaptus Therapeutics (INDP) has outperformed CorMedix (CRMD) over the past year, gaining 52.4% versus a loss of 45.6%. Over five years, CRMD leads with a +3.9% price change compared with -98.3% for INDP. Indaptus Therapeutics is the larger company by market cap ($433.2 million vs $419.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | INDP |
|---|---|---|
| Share price | $5.27 | $2.82 |
| Market cap | $419.16M | $433.16M |
| 1-day change | +3.74% | -9.90% |
| YTD return | -54.69% | -3.09% |
| 1-year return | -45.56% | +52.43% |
| 5-year return | +3.94% | -98.26% |
| P/E ratio (TTM) | 8.23 | — |
| Forward P/E | 15.06 | — |
| EPS (TTM) | $0.64 | $-3.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $311.71M | — |
| Revenue growth (YoY) | +617.03% | — |
| Net income (latest FY) | $163.06M | $-20.85M |
| Gross margin | 88.46% | — |
| Operating margin | 48.17% | — |
| Net margin | 52.31% | — |
| 52-week high | $13.02 | $5.96 |
| 52-week low | $4.47 | $0.92 |
| Distance from 52-week high | -59.52% | -52.68% |
| Analyst consensus | buy | — |
| Avg. price target upside | +161.86% | — |
| Average volume | 1.44M | 712.87K |
| Shares outstanding | 79.54M | 153.60M |
| Employees | 191 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INDP has outperformed CRMD by 98.0 percentage points over the past year.
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CRMD vs INDP FAQ
Which is bigger, CorMedix or Indaptus Therapeutics?
Indaptus Therapeutics (INDP) is larger, with a market capitalization of $433.16M compared with $419.16M for CorMedix (CRMD).
Which stock has performed better over the past year, CRMD or INDP?
INDP returned +52.43% over the past 12 months, compared with -45.56% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and Indaptus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.